RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:93571

Dense deposit disease

high confidenceSubtype of disorder

Also known as: Membranoproliferative glomerulonephritis type 2

Publications

1,151

91.5th percentile

Trials

14

Interventional, condition-specific

Researchers

1,200

Distinct authors in sample

Gene link

—

Readiness

2/6

Stages with a signal

Clinical definition (Orphanet)

A histological subtype of C3 glomerulopathy characterized by C3 deposition in renal tissue in the absence or near-absence of immunoglobulin deposits, in a patient with the classic clinical features of glomerulonephritis and electron microscopic findings of highly electron-dense intra-membranous, osmiophilic deposits.

How rare: 1-9 / 1 000 000 — roughly one to nine people per million. In a city the size of Kolkata, perhaps a few dozen.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (2)

Mesangiocapillary glomerulonephritis type 2 · membranoproliferative glomerulonephritis type 2

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    1,151 matched papers (626 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialPresent

    14 matched on ClinicalTrials.gov (1 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

1,151

1,151 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

1,151 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

626 in the last 10 years · high confidence · 91.5th percentile (publications denominator)

Phrase hits: 1,151 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,200

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Bomback AS9 papers · 2026

    Division of Nephrology, Columbia University Irving Medical Center, New York, New York, USA.

    Papers in Europe PMC
  2. 02
    Caravaca-Fontán F9 papers · 2026

    Department of Nephrology, Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain.

    Papers in Europe PMC
  3. 03
    Praga M7 papers · 2026

    Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain.

    Papers in Europe PMC
  4. 04
    Sethi S7 papers · 2026

    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.

    Papers in Europe PMC
  5. 05
    Fakhouri F5 papers · 2026

    Lausanne University Hospital, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.

    Papers in Europe PMC
  6. 06
    Fervenza FC5 papers · 2024

    Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.

    Papers in Europe PMC
  7. 07
    Kavanagh D5 papers · 2026

    National Renal Complement Therapeutics Centre, Newcastle University, UK.

    Papers in Europe PMC
  8. 08
    Pickering MC5 papers · 2026

    Imperial College, London, UK.

    Papers in Europe PMC
  9. 09
    Ariceta G4 papers · 2026

    Department of Pediatric Nephrology, University Hospital Vall d'Hebron, Autonomous University of Barcelona, Barcelona, Spain.

    Papers in Europe PMC
  10. 10
    Cavero T4 papers · 2026

    Department of Nephrology, Hospital Universitario 12 de Octubre, Madrid, Spain.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

14

interventional trials for this specific condition

14 interventional trials matched this specific condition name; 1 currently recruiting in our sample.

Data as of 27 July 2026

14 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 93.1th percentile).

high confidence · 93.1th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

14 interventional trials matched after quoted-phrase search and title/condition post-filter.

Observational and natural-history studies

1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

Recruiting or not-yet-recruiting

Open the complete matched search on ClinicalTrials.gov

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Dense deposit disease" OR "Membranoproliferative glomerulonephritis type 2" OR "Mesangiocapillary glomerulonephritis type 2"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Dense deposit disease" OR "Membranoproliferative glomerulonephritis type 2" OR "Mesangiocapillary glomerulonephritis type 2"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 14 interventional · 1 observational · 1 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T04:24:59.206Z